PARP1 deficiency mitigates amyloid pathology, neurodegeneration, and cognitive decline in a familial Alzheimer’s disease model
Proceedings of the National Academy of Sciences · 2026
DOI: 10.1073/pnas.2525028123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2026. Verfasst von Aanishaa Jhaldiyal und 18 weiteren Autor:innen. Beteiligte Einrichtung: Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD 21205. Hauptthemen laut MEDLINE: Alzheimer Disease, Poly (ADP-Ribose) Polymerase-1, Cognitive Dysfunction. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, Alzheimer's Association (AA), NIGMS NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Poly(ADP-ribose) (PAR) polymerase 1 (PARP1) has been implicated in DNA damage responses and neuroinflammation in Alzheimer’s disease (AD), yet its role in amyloid-beta (Aβ) pathology remains unclear. Here, we show that PARP1 activation drives Aβ pathology and neurodegeneration. Using a sensitive enzyme-linked immunosorbent assay, we observed significantly elevated PAR levels in the cerebrospinal fluid (CSF) of patients with mild cognitive impairment (MCI) and AD compared to controls. In vitro, oligomeric Aβ 1-42 activated PARP1 and induced DNA damage, while genetic or pharmacological inhibition of PARP1 conferred neuroprotection. In vivo, PARP1 knockout in the 5XFAD mouse model of amyloidosis led to reduced amyloid plaque burden, preserved synaptic and neuronal integrity, attenuated glial activation and neuroinflammation, and rescued cognitive deficits. Mechanistically, PARP1 deficiency decreased amyloid precursor protein and BACE1 levels, altered γ-secretase complex composition, and enhanced Aβ degradation via neprilysin. These findings position PARP1 as a critical mediator of Aβ toxicity and neurodegeneration, suggesting its inhibition as a promising therapeutic strategy for AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD 21205.
- Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205.
- Department of Physiology, Pharmacology and Therapeutics, The Johns Hopkins University School of Medicine, Baltimore, MD 21205.
- Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98104.
- Lerner Research Institute, Genomic Medicine, Cleveland Clinic, Cleveland, OH 44195.
ORCID-Profile: Aanishaa Jhaldiyal, Manisha Kumari, Lauren C Guttman, Trupti Tripathi, Justin Wang, Shraddha Pandya, Marilyn Albert, James B Leverenz, Tae-In Kam, Ted M Dawson, Valina L Dawson
Förderung
- NIA NIH HHS
- Alzheimer's Association (AA)
- NIGMS NIH HHS
- HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
- HHS | NIH | National Institute on Aging (NIA)
- Edward N. and Della L. Thome Memorial Foundation (Thome Memorial Foundation)
- Alzheimer’s Association
Zitieren
APA
Jhaldiyal, A., Kumari, M., Guttman, L. C., Tripathi, T., Khan, M. R., Wang, J., Biswas, D., Pasupuleti, A., Aggarwal, A., Pandya, S., Chou, S. C., Panicker, N., Monghekar, A., Albert, M., Bekris, L. M., Leverenz, J. B., Kam, T. I., Dawson, T. M., & Dawson, V. L. (2026). PARP1 deficiency mitigates amyloid pathology, neurodegeneration, and cognitive decline in a familial Alzheimer’s disease model. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2525028123
Vancouver
Jhaldiyal A, Kumari M, Guttman LC, Tripathi T, Khan MR, Wang J, et al. PARP1 deficiency mitigates amyloid pathology, neurodegeneration, and cognitive decline in a familial Alzheimer’s disease model. Proceedings of the National Academy of Sciences. 2026. doi:10.1073/pnas.2525028123
BibTeX
@article{Jhaldiyal2026,
author = {Jhaldiyal, Aanishaa and Kumari, Manisha and Guttman, Lauren C and Tripathi, Trupti and Khan, Mohammed Repon and Wang, Justin and Biswas, Devanik and Pasupuleti, Abhishek and Aggarwal, Akansha and Pandya, Shraddha and Chou, Shih-Ching and Panicker, Nikhil and Monghekar, Abhay and Albert, Marilyn and Bekris, Lynn M and Leverenz, James B and Kam, Tae-In and Dawson, Ted M and Dawson, Valina L},
title = {PARP1 deficiency mitigates amyloid pathology, neurodegeneration, and cognitive decline in a familial Alzheimer’s disease model},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
doi = {10.1073/pnas.2525028123}
}
EUVIMED